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Nonsteroidal Anti-inflammatory Drugs for Sciatica
An Updated Cochrane Review
Eva Rasmussen-Barr, PhD,,y Ulrike Held, PhD,z Wilhelmus J.A. Grooten, PhD,y
Pepijn D.D.M. Roelofs, PhD,§ Bart W. Koes, PhD,{ Maurits W. van Tulder, PhD,jj
Maria M. Wertli, MD, PhDz
Study Design. Systematic review and meta-analysis.
Objective. To determine the efficacy of nonsteroidal anti-inflam-
matory drugs (NSAIDs) on pain reduction, overall improvement,
and reported adverse effects in people with sciatica.
Summary of Background Data. NSAIDs are one of the most
frequently prescribed drugs for sciatica.
Methods. We updated a 2008 Cochrane Review through June
2015. Randomized controlled trials that compared NSAIDs with
placebo, with other NSAIDs, or with other medication were
included. Outcomes included pain using mean difference (MD,
95% confidence intervals [95% CI]). For global improvement
and adverse effects risk ratios (RR, 95% CI) were used. We
assessed level of evidence using the Grades of Recommen-
dation, Assessment, Development and Evaluation approach.
Results. Ten trials were included (N¼1651). Nine out of 10
trials were assessed at high risk of bias. For pain reduction
(visual analog scale, 0 to 100) NSAIDs were no more effective
than placebo (MD 4.56, 95% CI 11.11 to 1.99, quality of
evidence: very low). For global improvement NSAIDs were more
effective than placebo (RR 1.14 [95% CI 1.03 to 1.27], low
quality of evidence). One trial reported the effect of NSAIDs on
disability with very low-quality evidence that NSAIDs are no
more effective than placebo. There was low-quality evidence
that the risk for adverse effects is higher for NSAID than placebo
(RR 1.40, 95% CI 1.02 to 1.93).
Conclusion. Our findings show very low-quality evidence that
the efficacy of NSAIDs for pain reduction is comparable with
that of placebo, low-quality evidence that NSAIDs is better than
placebo for global improvement and low-quality evidence for
higher risk of adverse effects using NSAIDs compared with
placebo. The findings must be interpreted with caution, due to
small study samples, inconsistent results, and a high risk of bias
in the included trials.
Key words: analgesics, Cochrane Review, low-back pain/drug
therapy, medication, meta-analysis, nonsteroidal anti-
inflammatory drug/adverse effects, pain management,
rehabilitation, sciatica/drug therapy, systematic review.
Level of Evidence: 1
Spine 2017;42:586–594
L
ow back pain (LBP) is one of the most common
medical disorders in the world,1,2 affecting functional
capacity and work absence and resulting in personal
suffering and huge socioeconomic cost.1,3 Sciatica is an
important subgroup of LBP. The prevalence of sciatica
varies depending on the time period studied: lifetime preva-
lence is reported as between 12.2% and 43%, period preva-
lence between 2.2% and 34%, and point prevalence
between 1.5% and 13.4%.4 The prognosis is considered
to be worse and more disabling than common LBP.4–6 The
clinical course of acute sciatica, however, is in general
considered to be favorable, and most pain and disability
resolve within a couple of weeks.6 The term ‘‘sciatica’’
describes a symptom and not a specific diagnosis.5–10
Clinical symptoms associated with sciatica are leg pain
radiating below the knee and into the foot and toes, muscle
weakness, sensory changes such as pins and needles or
numbness following the dermal pattern, impaired reflexes,
or the presence of a positive straight leg raising test.4–6,11
Medication plays an important role in themanagement of
sciatica. NSAIDs are one of the most frequently prescribed
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pain drugs worldwide for treating sciatica 12 Many different
NSAIDs exist based on six major chemical structures that
differ in their dose, drug interactions, and adverse effects. The
main anti-inflammatory, antipyretic, and analgesic effect of
NSAIDs is based on the suppression of the cyclooxygenase
(COX)-1 and COX-2 enzymes. By blocking the COX
enzymes, vasodilation is reduced and inflammation relieved.
Furthermore, the synthesis of prostaglandins is blocked,
leading to reduced pain.13,14 The NSAIDs block the prosta-
glandin synthesis similar to steroids but without adverse
effects observed in steroids. However, NSAIDs are respon-
sible for various adverse effects; gastrointestinal, cardiovas-
cular, renal, and hepatotoxic adverse effects are described.15
The well-known gastrointestinal adverse effects of NSAIDs
are caused by blocking of the COX-1 enzyme, which leads to
a reduction in mucosal prostaglandin synthesis, and its pro-
tective effects. NSAIDs are therefore associated with an
increased risk for early gastrointestinal complications.
NSAIDs are recommended in clinical guidelines for scia-
tica,6,12,16 but a previous Cochrane review12 showed limited
evidence to support the efficacy of NSAIDs in sciatica. Our
primary objective was to update a previous Cochrane
review12 to determine the efficacy of NSAIDs in pain
reduction, overall improvement, and reported adverse
effects in people with sciatica.
MATERIAL AND METHODS
Types of studies
We included randomized controlled trials (RCTs) (double-
blind, single-blind, and open-label). We used no language
restriction. Trials included participants aged 16 years or
older with acute, subacute, and chronic (>12
weeks) sciatica.
Sciatica was defined as pain radiating to one or both legs
below the knee with some of the following signs; positive
straight leg raising test, or Lase`gue sign presenting with
numbness, pins or needles in a dermatomal distribution; and
muscle weakness or reflex changes or both in a myotome
distribution. We excluded people with sciatica caused by
specific pathological entities such as infection, neoplasm,
metastasis, osteoporosis, rheumatoid arthritis, or fractures.
We included RCTs that investigated one or more types of
NSAIDs. Additional interventions were allowed if there was a
contrast for the treatment with NSAIDs in the trial. We
considered the following comparator groups: (1) placebo,
(2) otherNSAIDs, and (3) other pharmacological agents, alone
or in combination (e.g., corticosteroids, muscle relaxants,
antidepressants). We excluded trials that compared NSAIDs
in combination with other pharmacological agents or non-
pharmacological treatments compared with another interven-
tion and NSAIDs compared with nondrug treatments.
Primary Outcomes
Included trials reported on (1) change in pain intensity (e.g.,
visual analog scale [VAS] or numerical rating scale), (2)
change in disability or functional status (e.g., Oswestry
Disability Questionnaire or Roland Morris Disability
Questionnaire, and (3) global measures (e.g., overall
improvement).
Secondary Outcomes
Secondary outcomes were reported adverse effects (pro-
portions of participants experiencing adverse effects of
NSAIDs) and the use of additional medication.
Search Methods for Identification of Studies
We searched Cochrane Central Register of Controlled Trials
(CENTRAL, the Cochrane Library, Issue 5, 2015; includes
the Cochrane Back and Neck [CBN] Review Group’s Trials
Register), MEDLINE, EMBASE, ClinicalTrials.gov, World
Health Organization International Clinical Trials, Registry
Platform (WHO ICTRP), and PubMed up until June 2015
for RCTs meeting the inclusion criteria. Additional trials
were identified through examination of references from
identified trials and systematic reviews. The complete search
strategy is presented in Appendix 1, http://links.lww.com/
BRS/B256.
Selection of Studies
Several authors independently screened titles, abstracts, and
keywords to identify trials that met the inclusion criteria.
We obtained and screened full texts of trials if either the
study seemed to meet the inclusion criteria or if inclusion
was uncertain. Disagreements were solved by consensus of
the review authors or third-party arbitration.
Data Extraction and Management
Three authors extracted the data from the trials on charac-
teristics of participants, interventions, primary and secon-
dary outcomes, adverse effects, and industry sponsorship of
the trial. Three authors extracted the mean difference (MD)
scores, standard deviations, and sample size using a data
extraction form. All disagreements were resolved through
discussion. In the case of potentially relevant missing infor-
mation in the papers, we contacted the corresponding
authors.
Data Synthesis
We analyzed dichotomous outcomes by calculating the risk
ratio (RR) with 95% confidence intervals (CI). We analyzed
continuous outcomes by calculating the MD with 95% CI.
We considered a P-value of less than 0.05 to be statistically
significant. We pooled data if two or more studies inves-
tigated comparable outcome measures. For the meta-
analyses (both the fixed- and the random-effects approach),
we considered only studies that used medications currently
on the market.
We assessed the quality of the evidence for all outcomes
regardless of whether there were sufficient data available
to use quantitative analyses to summarize the data.We rated
the quality of the evidence according to the Grades
of Recommendation, Assessment, Development and
Evaluation (GRADE) approach,17 recommended in the
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Cochrane Handbook18 and adapted in the updated CBN
guidelines.19 We graded trials on specific domains recom-
mended by the Cochrane CBN tool: (1) risk of bias, (2)
inconsistency, (3) indirectness, (4) imprecision, and (5) other
factors (e.g., publication bias).19 We used the statistical
software Review Manager (RevMan) Version 5.3 (The
Nordic Cochrane Centre, The Cochrane Collaboration,
Copenhagen).
Risk of Bias
Three review authors (E.R.B., M.W., W.G.) independently
assessed the risk of bias of the included trials based on
criteria described in the CBN’s tool for assessing risk of
bias.19 We defined high-quality studies as fulfilling six or
more of the validity criteria. We assessed the following
factors for other sources of potential bias: funding and other
biases such as (low) sample size and how the data were
presented.19 We did not downgrade the evidence when all
trials were judged as low risk of bias for all five categories.
We downgraded the evidence by one level when more than
three categories had a high or unclear risk. We downgraded
the evidence by two levels when four or more categories had
a high or unclear risk.
Inconsistency
We downgraded the quality of evidence by one level when
heterogeneity or variability in results was large (I2>80%)
and two levels when there was in addition inconsistency
arising from populations, interventions, or outcomes.17,19
Indirectness
We downgraded one level whether there was an uncertainty
about generalizability of the results in one area (e.g., popu-
lation, intervention, comparator, or outcome), and we
downgraded two levels when there was indirectness in
two or more areas.17,19
Imprecision
We downgraded by one level when trials included relatively
few participants and few events or had wide confidence
intervals around the estimate of the effect and when there
was only one trial and when there was more than one trial
and the total number of events was lower than 300 for
dichotomous data and 400 for continuous data.17,19 We
downgraded two levels if there were both few events, few
patients, and wide confidence intervals.
Publication Bias
The quality of evidence was downgraded by one level if the
funnel plots suggested publication bias.
RESULTS
We identified 2629 references, obtained full-text articles for
37 references with 10 RCTs20–28 (nine publications) meet-
ing the inclusion criteria (N¼1651) of which two trials27,28
were added compared with the original review29 (Figure 1,
Appendix 2, http://links.lww.com/BRS/B257).
Included Studies
Five trials used the currently recommended daily dose
of NSAIDs,20,21,26,27 whereas two22,28 used lower doses
(Table 1). Three trials investigated NSAIDs no longer
approved for human use.23–25 Most trials included smaller
samples (n¼25–59), whereas some21,26,27 included larger
samples (n¼171–532). Most trials included participants
seeking care for acute sciatica of less than 3 weeks’ duration.
Figure 1. Study flow diagram.
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The follow-up duration varied from 3 to 8 hours to 1 year.
The trials were conducted in the USA,24 Japan,28
Germany,20,27 Sweden,22,23 and in Norway.25,26
Description of Studies
NSAID Versus Placebo
Four trials 20,21,26,28 reported on pain relief (VAS 0 to 100),
one26 on functional outcome (Roland Morris Disability Ques-
tionnaire [RMDQ])at14daysand4weeks. Five trials21,23,25–27
reported on global improvement. Radin and Bryan24 did not
report how global improvement was measured and was
therefore not included. In all trials except one28 the use of
additional medication was allowed: paracetamol with or with-
out codeine, promethazine25 and levomepromazine.26
NSAID Versus NSAID
One trial27 compared lornoxicam with diclofenac, whereas
one21,27 compared meloxicam (7.5/15mg) with diclofenac
(150mg).
NSAID Versus Other Drugs
Braun and Huberty20 compared ketoprofen orally with a
combination of steroids and phenylbutazone (intramuscular
TABLE 1. Summary of Trials and Substances Used
ATC Group,
Trial Substance Daily Dose
Recommended
Maximum Dose
Treatment
Duration
Sample Size
Calculation
Participants Per
Group (n)
Butylpyrazolidin
Grevsten 1975 Phenylbutazone
(Butazolidin) IM
day 1;
phenylbutazone
(Butazolidin
Alka) orally day
2 to 4
0.6 g IM day 1,
0.6 g day 2 to 4
by mouth, 0.3 g
day 5 to 14
No longer
approved for
human use
14 days No 36
Weber 1980 Phenylbutazone
(Butazolidin
Alka)
600mg day 1 to
3, 300mg day 4
to 5
No longer
approved for
human use
5 days No 59
Radin 1968 Phenylbutazone 600mg day 1 to
2, 300 to 800mg
day 3 to 8
No longer
approved for
human use
8 days No 25
Acetic acid derivatives
Goldie 1968 Indomethacin 75 mg 225 mg 14 days No 25
Herrmann 2009 Diclofenac 100mg day 1
and 5; 150mg
day 2 to 4
150 to 200 mg 4 days 50 per group 57
Dreiser 2001 Diclofenac 150 mg 150 to 200 mg 14 days 150 per group 162
Kanayama 2005 Diclofenac vs.
active
treatment
75 mg 150 to 200 mg 14 days 20 per group 20
Oxicams
Dreiser 2001
(placebo-
controlled trial)
Meloxicam
7.5/15 mg
7.5/15 mg 15 mg 7 days 150 per group 171/181
Dreiser 2001
(diclofenac-
controlled trial)
Meloxicam
7.5/15 mg
7.5/15 mg 15 mg 14 days 150 per group 164/163
Weber 1993 Piroxicam 100mg day 1 to
2, 20mg day
3 to 14
20 mg 14 days No 120
Herrmann 2009 Lornoxicam 24mg day 1;
16mg day 2
to 4; 8mg day
5
16 mg 5 days 50 per group 57
Propionic acid derivative
Braun 1982 Ketoprofen vs.
active
treatment
200mg IM day 1
to 3, 300mg
orally þ supp
day 4 to 8
200 (max 300)
mg
9 days No 17
Fenamates, coxibs, or others
No studies — — — — — —
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followed by oral), whereas one trial28 compared diclofenac
(75mg/day) with a serotonin or 5-hydroxytryptamine (5-
HT) inhibitor.
Excluded Studies
We excluded 27 studies during full-text review (Figure 1).
The main reasons for exclusion were either that the partici-
pants were not suffering from sciatica or that the study
design was not an RCT.
Risk of Bias in Included Studies
Risk of bias assessment is presented in Figure 2. One27 of the
10 trials fulfilled six or more criteria and was judged at low
risk of bias. The other studies had selection bias, detection
bias, and lack of clarity regarding compliance. All studies
had either a high risk of bias or an unclear risk of bias
regarding industry funding, compliance with the study
medication, or small sample sizes.
Effects of Interventions
Change in Pain Intensity
NSAIDs Versus Placebo. Three trials (four treatment
arms)21,26,27 (N¼918) reported on pain reduction (VAS)
and were included in the meta-analysis (Figure 3). Dreiser
et al21 found meloxicam 7.5mg superior to placebo, but
15mg did not increase the effect. We found very low-quality
evidence that NSAIDs are no better than placebo (MD4.56,
95% CI 11.11 to 1.99, random-effects model, I2¼82%).
When excluding one trial27 with a very short follow-up
duration, the pooled MD was 0.09 (95% CI 9.89 to
9.71, I2¼86%). We downgraded the evidence two levels
due to high risk of bias and one level due to inconsistency.
NSAIDs Versus NSAID. Two trials21,27 compared the effect
of two types of NSAIDs. There was no difference in mean
pain reduction between lornoxicam27 and meloxicam (7.5/
15mg)21 compared with diclofenac.
Figure 2. Risk of bias summary: review authors’ judgements
about each risk of bias item for each included study.
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NSAIDs Versus Other Drugs. Two trials20,28 compared
NSAIDs with other drugs. Braun and Huberty20 compared
ketoprofen intramuscular injection followed by oral ketap-
rofen with corticosteroids in addition to phenylbutazone
intramuscular followed by oral corticosteroid in addition to
phenylbutazone. Kanayama et al28 compared a serotonin or
5-HT inhibitor with diclofenac (75mg/day). No difference
in pain reductionwas found between the treatments in either
of the trials.
Change in Disability. Weber et al26 (n¼214) compared
NSAIDs (piroxicam) with placebo for change in functional
outcomes (RMDQ¼ after 14 days and 4 weeks. There was
very low-quality evidence that NSAIDs are no better than
placebo, due to high risk of bias and imprecision.
Global Improvement
NSAID Versus Placebo. Five trials21,23,25–27 with a total of
846 participants reported on global improvement. We used
three21,26,27 of the five trials (N¼753) in the meta-anaysis
as two trials23,25 used medications no longer on the market
(phenylbutazone) (Figure 4).We found low-quality evidence
that NSAIDs are more effective than placebo for global
improvement (RR 1.14, 95% CI 1.03 to 1.27; fixed-effect
model, I2¼0%). The corresponding number needed to
treat for an additional beneficial outcome (NNTB) was
12 participants based on the absolute risk difference of
0.09 (95% CI 0.02 to 0.16). We downgraded the evidence
two levels due to high risk of bias.
NSAID VersusNSAID. Two trials21,27 showed no difference
in global improvement when lornoxicam and meloxicam
were compared with diclofenac.
NSAID Versus Other Drugs. Two trials20,28 compared
NSAIDs with other drugs. Ketoprofen intramuscular injec-
tion followed by ketoprofen oral compared with cortico-
steroids in addition to phenylbutazone intramuscular
followed by oral corticosteroid in addition to phenylbuta-
zone was comparable effective.20 No differences were
found between serotonin or 5-HT inhibitor and diclofenac
(75mg/day).28
Adverse Effects
NSAID Versus placebo. The meta-analysis included four
trials21,22,26,27 (N¼967), one with two treatment arms27
that used NSAIDs currently on the market (Figure 5). Two
trials did not report adverse effects,20,28 whereas one trial25
found no adverse effects. The pooled analyses showed low-
quality evidence for increased risk of adverse effects of
NSAIDs compared with placebo (RR 1.40, 95% CI 1.02
to 1.93). When excluding one trial26 assessed with a high
risk of bias the summary estimate was similar (RR 1.42,
95%CI 0.98 to 2.07). The corresponding number needed to
harm was 20 participants for one adverse effect based on an
absolute risk difference of 0.05 (95% CI 0.00 to 0.10).
Most adverse effects were reported to be mild and
comprised gastrointestinal problems described as nausea,
dyspepsia, epigastric burning, abdominal pain, and in
addition headache and dizziness. No perforation, ulcer-
ation, or bleeding of the upper gastrointestinal tract
was reported. One life-threatening adverse event occurred:
an anaphylactic shock requiring steroid therapy in the
meloxicam 7.5mg group (treatment related), and there
was one serious adverse event with deterioration of back
Figure 3. Forest plot of comparison: nonsteroidal anti-inflammatory drug (NSAID) versus placebo. Change in pain intensity summary.
Figure 4. Forest plot of comparison: nonsteroidal anti-inflammatory drug (NSAID) versus placebo. Global improvement.
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pain in the placebo group (not treatment related). Both
participants recovered.
NSAID Versus NSAID. Two trials21,27 comparing NSAIDs
to NSAIDs reported no difference in adverse effects.
NSAID Versus Other Drugs. One trial20 did not report on
adverse effects, whereas one trial28 reported no adverse
effects.
Additional Use of Pain Medication. In participants treated
with meloxicam 7.5mg less pain medications was used.21
An increase in the dose of meloxicam to 15mg did not
decrease the need of additional pain medication. Two
trials25,26 found no difference in the use of additional pain
medication between NSAIDs and placebo and one20 no
difference compared with other medication.
DISCUSSION
This updated Cochrane Review included 10 trials reported
in nine publications.20–28 Only two additional trials27,28
were included compared with the original review.29 Given
the high risk of bias in all trials but one,27 there is low
to very low-quality evidence of the efficacy of NSAIDs
compared with placebo or other drugs in the treatment
of sciatica. Small study samples, incomplete outcome
reporting, and inconsistency affected the grading of the
quality of the evidence. Even if more participants with
NSAIDs experienced global improvement compared with
placebo, the grading of the evidence of the pooled analyses
was low.
Recent reviews29–31 have included trials reporting on the
efficacy of NSAIDs in acute and chronic LBP and with or
without sciatica. Pinto et al30 included five of the trials
included in our review, whereas excluding three20,24,25 due
to unclear randomization and concluded that the graded
evidence for the efficacy of NSAIDs is low due to limitations
of study design and inconsistency. We chose to include and
report on all trials even if assessed with a high risk of bias for
full transparency on the efficacy of NSAIDs and sciatica.
We, however, excluded two trials24,25 from the meta-
analyses as these trials used NSAIDs no longer on the
market. Furthermore, we excluded Weber et al26 due to
high risk of bias to conduct a sensitivity analysis for the
outcome of adverse effects. Even so, the finding of the
sensitivity analysis did not change the results. In all, our
findings are consistent with those of Pinto et al30 for the
effect of overall pain reduction. Furthermore, Wong et al31
concluded in a review that there was inconsistent evidence
for the treatment of recent onset LBP with radiculopathy.
Based on our thorough literature search, and other recently
published reviews in the same area30,31 we find our evidence
applicable. In addition, our results are in line with the
original Cochrane Review29 on the efficacy of NSAIDs
on sciatica.
Eight of the included trials reported on acute sciatica of
less than 3 weeks’ duration, whereas two24,25 provided no
information on the duration. The external validity of our
review thus only extends to those suffering from sciatica for
less than 3 weeks. In addition, only one trial26 reported on
the effect of NSAIDs on disability,26 with very low-quality
evidence that NSAIDs are no more effective than placebo.
The risk for adverse effects of NSAIDs is well docu-
mented in the literature.32,33 All but two trials,20,28 reported
on the risk of adverse effects for NSAIDs compared with
placebo. Our finding of an increased risk for adverse effects
was graded as low-quality evidence, and in addition the
included trials did not have enough power to detect rare
adverse effects. Thus, based on our findings we cannot draw
any conclusion on the long-term effects of NSAIDs in
sciatica. Although the GRADE quality of evidence was
low due to the small study sample and a high risk of bias,
the findings of risk for adverse effects in the present review
are consistent with the literature. A recent guideline34
recommend the use of NSAIDs for sciatica with the lowest
effective dose for the shortest possible period of time and to
take adverse effects into account.
Our review expands the current evidence on the treat-
ment efficacy of NSAIDs in sciatica with regard to several
aspects. In addition to pain reduction, we assessed the
effect on global improvement, finding that NSAIDs are
more effective than placebo for sciatica. However, this
finding must be treated with caution as some of the
trials27,28 allowed the use of additional pain medication
and showed inconsistent results. In addition, although three
trials20,25,26 found no difference between NSAIDs and
placebo with regard to the use of additional pain medi-
cation, one trial21 found less use of pain medication in the
NSAID group.28
Figure 5. Forest plot of comparison: nonsteroidal anti-inflammatory drug (NSAID) versus placebo. Adverse effect summary.
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The main limitations of the current review are the
number of trials available, the high risk of bias, and the
small sample size of included trials. Moreover, only
four21,22,27,28 of the included publications reported on a
power calculation. Another limitation is that we were not
able to perform meta-analyses for all outcomes. For the
outcome pain, heterogeneity of more than 80% between
trials indicated that there was a wide range in treatment
responses. As one study arm27 reported a short follow-up
of eight hourswe conducted a sensitivity analysis excluding
the short-term arm, finding that the effect on pain
reduction further decreased. To be able to detect if sub-
groups of participants with sciatica benefit from NSAIDs,
additional analyses may be conducted which in the present
review were not feasible due to insufficient trials and
specific treatment responses. A further limitation is that
only five trials assessed the treatment efficacy of currently
available drugs in the recommended daily dose.20,21,26,27
Moreover, two trials used lower doses of NSAIDs (over the
counter), which might explain less efficacy in those
trials.22,28
Due to the low number of included trials (n¼10) in the
present review, we decided to include all eligible trials in the
analyses even if assessed with a high risk of bias, using
various doses, or reporting different short treatment out-
come. We however conducted sensitivity analyses excluding
trials with a high risk of bias. A limitation for the outcome of
adverse effects is that for the individual studies there was
clearly not enough power to detect rare adverse events,
which means that we cannot fully exclude that potentially
rare event may occur.
CONCLUSION
Implications for Practice
We found that NSAIDS are no more effective than
placebo in short-term pain reduction (very low-quality
evidence). NSAIDs are associated with more global
improvement for sciatica at short-term follow-up (low-
quality evidence). One trial assessed disability, and found
no difference in effects between placebo and NSAIDs
with very low-quality evidence.When prescribing NSAIDs
in people with sciatica, the increased risk for adverse
effects (low-quality evidence), also in short treatment
duration, needs to be taken into account in the
treatment decision.
Implications for Research
We found two additional trials for this updated
review assessing the effect of NSAIDs compared to placebo
or other drugs in sciatica, compared with the original
review published in 2008. Most trials were assessed with
a high risk of bias and included small study samples. For
future studies on the efficacy of NSAIDs for sciatica, it
might be important to investigate meta-regressions of
defined subgroups of participants in methodologically
sound RCTs.
Key Points
A systematic review assessed the efficacy of
NSAIDs for sciatica.
Ten randomized trials were included (N¼ 1651).
Only one had a low risk of bias.
For pain relief in sciatica the literature does not
support the use of NSAIDs as there is very low
evidence that the efficacy of NSAIDs is
comparable to placebo treatment for sciatica in
pain relief.
For global improvement there is low-quality
evidence that NSAIDs are more effective
than placebo.
Adverse effects are more commonly reported
when using NSAIDs compared to placebo with
low-quality evidence.
The results of the review must be interpreted with
caution due to the high risk of bias in the included
trials and the overall low to very low-quality of
the evidence.
Supplemental digital content is available for this article.
Direct URL citations appearing in the printed text are
provided in the HTML and PDF version of this article on
the journal’s Web site (www.spinejournal.com).
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